In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia
Open Access
- 31 March 2021
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (4)
- https://doi.org/10.1128/AAC.01436-20
Abstract
Cefiderocol is a novel siderophore cephalosporin antibiotic with broad coverage against difficult-to-treat Gram-negative bacteria, including those resistant to carbapenems. Its activity against Stenotrophomonas maltophilia was investigated in vitro against clinical isolates and in lung infection models using strains either resistant (SR202006) or susceptible (SR201934, SR200614) to trimethoprim-sulfamethoxazole. Cefiderocol demonstrated potent in vitro activity against all 217 S. maitophilia clinical isolates tested (MIC50, 0.063 mu g/ml; MIC90, 0.25 mu g/ml). Cefiderocol also demonstrated low MICs against the trimethoprim-sulfamethoxazole-resistant S. maltophilia strains (i.e., SR202006; MIC, 0.125 mu g/ml). In a neutropenic mouse lung infection model, cefiderocol (30 mg/kg body weight and 100 mg/kg) demonstrated a significant, dose-dependent reduction in the lung viable bacteria cell count compared with untreated controls in S. maltophilia infection and was the only antibiotic tested to show a similar significant effect in a trimethoprim-sulfamethoxazole-resistant S. maitophilia infection. In immunocompetent rat lung infection models of S. maltophilia, humanized dosing of cefiderocol (2 g every 8 h) and meropenem (1 g every 8 h) revealed pharmacokinetic profiles similar to those in human subjects, and the humanized cefiderocol dosing significantly reduced the lung viable bacteria cell IV count compared with baseline controls, which received no intervention. Together, the results from these studies suggest that cefiderocol could provide an effective al- ternative treatment option for S. maltophilia infections in the lower respiratory tract, particularly strains resistant to empirical antibiotics, such as trimethoprim-sulfame- or thoxazole or minocycline.Keywords
Funding Information
- Shionogi
This publication has 21 references indexed in Scilit:
- In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016Antimicrobial Agents and Chemotherapy, 2018
- In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative BacteriaAntimicrobial Agents and Chemotherapy, 2018
- Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic TherapyFrontiers in Microbiology, 2017
- Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection ModelAntimicrobial Agents and Chemotherapy, 2017
- Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma PharmacokineticsAntimicrobial Agents and Chemotherapy, 2017
- In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)Antimicrobial Agents and Chemotherapy, 2017
- Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophiliaFrontiers in Microbiology, 2015
- Stenotrophomonas maltophilia: an Emerging Global Opportunistic PathogenClinical Microbiology Reviews, 2012
- Effect of thymidine on activity of trimethoprim and sulphamethoxazole.Journal of Clinical Pathology, 1978
- Thymidine concentrations in serum and urine of different animal species and manBiochemical Pharmacology, 1977